Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?

Rheumatology

Volumn 45, Issue 5, 2006, Pages 497-499

  Pincus, T ^a   Sokka, T ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE DURATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEALTH CARE ORGANIZATION; HUMAN; LOW DRUG DOSE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS;

EID: 33646188202     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel014     Document Type: Editorial

References (41)

1. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984;43:8-17.
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
3. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
4. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors. Ann Intern Med 1980;93:551-6.
5. Weinblatt ME. Rheumatoid arthritis: Treat now, not later!. Ann Intern Med 1996;124:773-4.
6. Emery P, Salmon M. Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995;54:944-7.
7. Pincus T. Rheumatoid arthritis: A medical emergency? Scand J Rheumatol 1994;23(Suppl. 100):21-30.
8. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 1993;32(Suppl. 1):28-37.
9. O'Dell JR. Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum 2002;46:283-5.
10. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy. Ann Intern Med 1999;131:768-74.
11. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75(Suppl. 6A):69-73.
12. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
13. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
14. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21: S179-S185.
15. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
16. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885-94.
17. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
18. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173-7.
19. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: A longitudinal study of 3035 patients. Am J Med 2003;115:371-6.
20. Sokka T, Kautiainen H, Häkkinen K, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004;31: 1073-82.
21. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.
22. Kavanaugh A, van Vollenhoven RF, Pincus T (guest eds). Benefit/risk of new drugs for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22(Suppl. 35):S1-S150.
23. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
24. Möttönen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
25. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
26. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9.
27. Vries-Bouwstra JK, Dijkmans BA, Breedveld FC. Biologics in early rheumatoid arthritis. Rheum Dis Clin North Am 2005;31:745-62.
28. Symmons D, Tricker K, Harrison M et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology 2005 (in press).
29. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996;35:1263-8.
30. Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997;10:381-94.
31. Welsing PMJ, van Gestel AM, Swinkels HL, Kiemeney LALM, van Riel PLCM. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
32. Pincus T, Sokka T. Partial control of Core Data Set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term damage: Evidence from longitudinal observations over 5-20 years. Clin Exp Rheumatol 2002;20: S42-S48.
33. Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. It's about integrating individual clinical expertise and the best external evidence. Br Med J 1996;312:71-2.
34. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: Methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
35. Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41:1037-41.
36. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15(Suppl. 17): S27-S38.
37. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983; 99:544-50.
38. Pincus T. Guidelines for monitoring of methotrexate therapy: 'evidence-based medicine' outside of clinical trials. Arthritis Rheum 2003;48:2706-9.
39. Pincus T, Sokka T. Rheumatoid arthritis. In: Rakel RE, Bope ET, eds. Conn's Current Therapy 2004. Philadelphia, PA: WB Saunders Company, 2004:1021-8.
40. Cronstein BN. Molecular therapeutics: Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
41. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 1996;136:76-8.